Details

Autor(en) / Beteiligte

• Rey, Juan R
• Merino Llorens, José Luis
• Iniesta Manjavacas, Ángel Manuel
• Rodríguez, Sandra Ofelia Rosillo
• Castrejón-Castrejón, Sergio
• Arbas-Redondo, Emilio
• Poveda-Pinedo, Isabel Dolores
• Tebar-Márquez, Daniel
• Severo-Sánchez, Andrea
• Rivero-Santana, Borja
• Juárez-Olmos, Víctor
• Martínez-Cossiani, Marcel
• Buño-Soto, Antonio
• Gonzalez-Valle, Luis
• Herrero-Ambrosio, Alicia
• López-de-Sá, Esteban
• Caro-Codón, Juan

Titel

Influence of statin treatment in a cohort of patients admitted for COVID-19

Ist Teil von

• Medicina clinica, 2022-06, Vol.158 (12), p.586

Ort / Verlag

Spain

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Statins have been proposed as potentially useful agents for modulating the host response in COVID-19. However, solid evidence-based recommendations are still lacking. Our aim was to study the association between statin use and clinical outcomes in a large cohort of hospitalized patients with SARS-CoV-2 infection, as well as the specific consequences of chronic treatment withdrawal during hospital admission. Retrospective observational study including 2191 hospitalized patients with confirmed SARS-CoV-2 infection. Mean age was 68.0±17.8 years and 597 (27.3%) patients died during follow-up. A total of 827 patients (37.7% of the whole sample), received chronic treatment with statins. Even though they underwent more frequent admissions in critical care units, chronic treatment with statins was not independently associated with all-cause mortality [HR 0.95 (0.72-1.25)]. During the whole hospital admission, 371 patients (16.9%) received at least one dose of statin. Although these patients had a significantly worse clinical profile, both treatment with statins during admission [HR 1.03 (0.78-1.35)] and withdrawal of chronic statin treatment [HR 1.01 (0.78-1.30)] showed a neutral effect in mortality. However, patients treated with statins presented more frequently hepatic cytolysis, rhabdomyolysis and thrombotic/hemorrhagic events. In this large cohort of hospitalized COVID-19 patients, statins were not independently associated with all-cause mortality during follow-up. Clinically relevant statin-associated adverse effects should be carefully monitored during hospital admission.